Home > News > T in Cheek: Buccal Testosterone as a New Treatment for Androgen Deficiency in Men
Reproductive Endocrinology
Read Time: 8 mins

T in Cheek: Buccal Testosterone as a New Treatment for Androgen Deficiency in Men

Published Online: April 5th 2012 US Endocrinology, 2006;(1):85-89 DOI: http://doi.org/10.17925/USE.2006.00.1.85
Authors: Bradley D Anawalt
Quick Links:
Article
Article Information
Article:

Male androgen deficiency has become a burgeoning area of public and commercial interest. Male androgen deficiency (commonly called male hypogonadism) is a common and important endocrinological syndrome defined by signs and symptoms of androgen deficiency plus low serum testosterone levels. Klinefelter syndrome, the most common congenital form of male hypogonadism, occurs in one in 500 men. In addition, the prevalence of men with low testosterone increases dramatically with age.

Male androgen deficiency has become a burgeoning area of public and commercial interest. Male androgen deficiency (commonly called male hypogonadism) is a common and important endocrinological syndrome defined by signs and symptoms of androgen deficiency plus low serum testosterone levels. Klinefelter syndrome, the most common congenital form of male hypogonadism, occurs in one in 500 men. In addition, the prevalence of men with low testosterone increases dramatically with age. For example, the Baltimore Longitudinal Study showed that the prevalence of low serum total testosterone levels rises from 12% of men under age 50 to 50% of men over age 80; the prevalence is even higher based on serum free testosterone levels. Based on these data, there appears to be an epidemic of male hypogonadism. However, a more accurate estimation of the prevalence of male hypogonadism is derived from the Male Massachusetts Aging Study that looked at least three symptoms suggestive of hypogonadism plus low serum testosterone levels in a cohort of over 1,000 men followed for an average of nearly nine years. In this study, 4.1% of men aged 40–49 years and 9.4% of men aged 60–70 years were hypogonadal. The Baltimore Longitudinal Study and Male Massachusetts studies highlight both the high prevalence of male hypogonadism and the importance of defining this syndrome based on symptoms, signs and labs that are consistent with androgen deficiency.
The recent recognition has led to many innovations in the diagnosis and treatment of male hypogonadism. In this article, I will briefly review the diagnosis and treatment of male hypogonadism. I will discuss the potential use of buccal testosterone, one of the most recent approved androgen formulations, as an example of the promise and pitfalls of new therapies for male hypogonadism that are under development.

Diagnosis of Male Hypogonadism

The diagnosis of male hypogonadism depends on symptoms and signs suggestive of androgen deficiency; the symptoms and signs vary based on whether hypogonadism occurs pre- or post-pubertally (see Table 1). The symptoms and most of the signs of male hypogonadism are very non-specific. When a man presents with symptoms or signs of hypogonadism, the clinician should determine the serum testosterone level with an accurate and reliable assay. The initial testosterone measurement ideally should be done on a blood sample drawn in the morning. It is crucial to confirm any borderline low testosterone level with a second measurement from a blood sample drawn early in the morning because up to 30% of men may have a normal testosterone level on repeat measurement.
There is some controversy about the best method for measuring circulating testosterone levels. However, an Endocrine Society expert panel recently recommended that total serum testosterone level should be the initial diagnostic test. Automated assays for total testosterone are widely available and are generally accurate and reliable for the diagnosis of male hypogonadism. Most circulating testosterone is avidly bound to sex hormone-binding globulin (~40%) or weakly bound to albumin (~58%); only about ~2% is unbound or free. Bioactive testosterone (the amount of testosterone in the serum that is available to produce end-organ and tissue effects) is thought to be the sum of the free testosterone and weakly bound testosterone. Generally, total testosterone and bioactive testosterone levels parallel, but, in many clinical settings, sex hormone binding globulin levels may be significantly altered (e.g. older men, obese men, men with diabetes mellitus or who are treated with anti-epileptics or corticosteroids).
Accurate assays for free and weakly bound testosterone levels are not available at many local laboratories. There are accurate assays that directly measure serum free and weakly bound testosterone levels by equilibrium dialysis and ammonium precipitation respectively. It is less expensive and more convenient to use a validated formula to calculate free and weakly bound testosterone levels (using total testosterone, sex hormone-binding globulin and albumin levels plus known affinity constants). These calculated measurements correspond well to values obtained by the accurate direct assays, and national commercial laboratories offer these calculated free and weakly bound testosterone measurements. It may be useful in some cases to measure free and weakly bound testosterone levels when total testosterone levels are equivocal or in patients with suspected abnormalities in sex hormone binding globulin or albumin levels. Assays that measure free testosterone by an automated analog method are widely available, inexpensive and notoriously inaccurate; these assays for free testosterone should not be used.
When serum testosterone levels are found to be low, reversible causes should be identified and corrected if possible. For example, suppressed testosterone levels commonly occur with acute or chronic illness, medications such as corticosteroids or opiates, and many recreational drugs. Testosterone levels should be re-measured at least one month after resolution or in the quiescent phase of systemic illnesses and at least one month after cessation of opiates, corticosteroids and other drugs that affect the gonadal axis.
When the diagnosis of male hypogonadism has been confirmed and reversible causes have been corrected, then the clinician should measure serum gonadotropin (FSH and LH) levels to distinguish between primary (testicular) and secondary (pituitary-hypothalamic) hypogonadism. Serum LH level is a better marker for low testosterone secretion, but LH levels fluctuate significantly throughout the day. Reproducibly elevated LH levels confirm primary hypogonadism even when serum testosterone levels are low-normal, and elevated FSH levels are useful to verify primary hypogonadism.
For patients with primary hypogonadism, further evaluation is unnecessary. Karotyping for Klinefelter’s syndrome, the most common form of primary hypogonadism is occasionally helpful, but serum karyotyping is costly. Most patients with Klinefelter’s syndrome can be easily recognized based on physical exam findings (very small, firm testes) plus elevated serum gonadotropin levels. Patients with secondary hypogonadism (low or inappropriately normal gonadotropins levels) need a directed evaluation to exclude common causes such as a large pituitary tumor, hyperprolactinemia, hemochromatosis, Cushing’s syndrome, and sleep apnea.
The most difficult diagnostic dilemma is the evaluation of an older man with slightly low testosterone levels and normal or slightly elevated gonadotropins levels. This clinical scenario is very common and has been dubbed andropause. Andropause has excited much interest in the lay press as a potential reversible cause of frailty associated with aging. The limited data currently available do not support widespread use of androgen supplementation to older men with slightly low testosterone levels.

Effects of Androgen Replacement Therapy

When the diagnosis of hypogonadism has been established, the clinician and patient must then determine if the benefits of androgen therapy warrant the potential risks and cost. For patients with unequivocal hypogonadism and no contraindications to androgen replacement therapy (e.g. untreated prostate or breast cancer, severe bladder outlet obstruction, untreated sleep apnea, or polycythemia), the benefits outweigh the risks of androgen replacement therapy. In some men with some manifestations of hypogonadism and borderline low testosterone levels, a trial of androgen therapy may be reasonable. Before beginning a trial of androgen therapy in instances where the diagnosis is equivocal, it is particularly important that the clinician document that he discussed the controversy and risks and benefits of androgen supplementation therapy with the patient.
Androgens affect a broad range of tissues, organs and physiological functions including sexual function, brain, muscle, bone, prostate, and the cardiovascular system. I will review briefly some of the important effects of androgens. There are many excellent recent reviews for readers interested in further details.

Benefits of Androgen Replacement Therapy
Sexual Function

Studies using a wide variety of formulations have shown an improvement of sexual desire, sexual satifaction and sexual performance. It is generally thought that younger men may have normal sexual function with subnormal testosterone levels, but older men may have a dose-dependent effect of testosterone on sexual function.

Lean Body Mass, Strength and Fat Mass

Most studies have shown moderate increases (1–5kg) of lean body mass when androgen replacement therapy, but a few trials have shown no effect. Several small studies have shown increased strength in at least one muscle group and two studies have shown improvement in functional tests of leg strength and balance5,15,16.A recent large cohort study reported that hypogonadal older men have decreased balance and increased risk of falls, but it remains unclear of androgen therapy would reduce this risk of falls.

Bone Density and Fractures

Most trials show that testosterone replacement therapy increases bone mineral density in men with low baseline testosterone levels. It is likely that the duration and degree of testosterone deficiency, the mode of testosterone delivery and the average testosterone levels achieved during therapy affect the degree of bone mineral density increase. For example, studies using sublingual testosterone in younger hypogonadal men or a transdermal testosterone patch system in older hypogonadal men did not significantly increase bone mineral density in hypogonadal men whereas a study of intramuscular testosterone therapy given to older hypogonadal men resulted in very significant increases in spine and hip bone mineral density. It is likely that the lower pre-treatment and higher average treatment levels achieved in the intramuscular testosterone study explain the increased bone mineral density compared to the sublingual and transdermal testosterone trials. Although epidemiological trials suggest that male hypogonadism is an important risk factor for osteoporotic fracture, there has not yet been an adequately powered, long-term clinical trial of the effects of androgen replacement on osteoporotic fracture in hypogonadal men.

Mood and Sense of Well-being

The majority of clinical trials have demonstrated an improvement of mood and sense of well-being in hypogonadal men treated with a variety of androgen replacement formulations. Mood, like sexual function, tends to improve early in the course of therapy and then plateau.

Risks of Androgen Replacement Therapy
Prostatic Disease

Most studies of androgen replacement therapy have shown that androgen replacement therapy increases prostatic size within the normal range for age. Androgen replacement therapy does not appear to alter micturition or increase the incidence of bladder outlet obstruction symptoms, but virtually all clinical trials exclude men with pre-treatment symptoms or the diagnosis of bladder outlet obstruction. The effects of testosterone androgen replacement therapy on the risks of prostate cancer are controversial. Testosterone therapy probably does not cause de novo prostate cancer, but it can promote the growth of pre-existing prostate cancer. In general, androgen replacement therapy to older men stimulates a small increase in serum prostate specific antigen (0.3-0.6 ng/mL) that stabilizes after three to six months of therapy. If the serum prostate specific antigen increases more than 1.4 ng/ml during a year of androgen therapy, then a urological evaluation is indicated.

Cardiovascular Disease

Although male gender is an established risk factor for coronary artery disease, androgens do not appear to increase the risk of ischemic heart disease. Epidemiological studies show that the risk of coronary artery disease tends to occur more frequently in men with lower serum testosterone levels, and hypogonadal men with established coronary artery disease who are treated with androgen replacement therapy have fewer signs of ischemia during exercise than placebo-treated hypogonadal men with established coronary artery disease. In addition, androgen replacement therapy tends to have favorable effects overall on risk factors for coronary artery disease. Although androgen replacement therapy causes small, but significant decreases in high-density lipoprotein cholesterol levels, it causes larger decreases in atherogenic low-density lipoprotein cholesterol levels and causes favorable changes in body composition.

Er ythropoeisis

Testosterone therapy stimulates erythropoiesis and may cause erythrocytosis, particularly in older men. Men who are treated with androgen replacement therapy should be periodically monitored with complete blood counts.

Treatment Options

There are now a myriad of androgen replacement treatment options: oral, buccal, transcutaneous (patches and gels), and short and long-acting injectable formulations that are being used in the US and around the world. It is beyond the scope of this brief review to discuss each of the formulations in depth, but each formulation has its advantages and disadvantages. I shall compare the most recently approved new formulation, buccal testosterone, with other approved formulations and will use it as a model for the promise and pitfalls of potential formulations of androgen replacement therapy that are being developed.

Buccal Testosterone

Steroid hormones are readily absorbed across the buccal mucosa into the systemic circulation and bypass first-pass hepatic metabolism. A small pilot study of a proprietary buccal testosterone tablet showed that peak testosterone levels were achieved within 30 minutes of application but testosterone levels returned to baseline within four to six hours. A newer proprietary buccal testosterone formulation, Striant®, was developed that is rapidly absorbed and maintains serum testosterone levels within the normal range for 12 hours. Initial clinical trials have shown that Striant (30mg every 12 hours) maintains serum testosterone levels in the normal range for a 24-hour period for 85–93% of hypogonadal men. The pharmakinetic profile compares favorably with transcutaneous testosterone patch and gel systems that are administered once daily on the torso. In a three-month safety trial, about 10% of patients withdrew because of application problems or intolerance with a few of weeks of intiating Striant‚ therapy. About 16% of the men who completed the three-month trial had either gum irritation or inflammation, and 3% withdrew because of oral adverse events.
The primary advantage of Striant is its mode of administration: most patients prefer an oral route for medications. There are other formulations of oral androgen replacement therapy: alkylated androgens and oral testosterone undecanoate. However, alkylated androgens cause hepatotoxicity, and Striant appears to have a longer-half and offer more stable testosterone levels than oral testosterone undecanoate. Although there have been no head-to-head comparison trials of Striant vs oral testosterone undecanoate, testosterone levels may vary significantly with oral testosterone undecanoate administration, and some men may have to take oral testosterone undecanoate three times daily. Many patients may prefer Striant over intramuscular injections of testosterone enanthate or cypionate every seven to 14 days because the discomfort of injections and to avoid the supraphysiological peaks of testosterone that occur two to three days after injection of these testosterone esters.■
This article containing references is continued with references and an additional figure in the Reference Section on the website supporting this briefing (www.touchendocrinedisease.com).

Article Information:

Further Resources

Share this Article
Related Content In Reproductive Endocrinology
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72